ALK and non-small cell lung carcinoma: Anaplastic lymphoma kinase (ALK) inhibitors, such as crizotinib, alectinib, and ceritinib, are currently developed and are among the treatment options for ALK rearrangement-positive lung cancer, which accounts for 3%–5% of all cases of NSCLC.